Premium
Polyglutamine‐Expanded Ataxin‐3: A Target Engagement Marker for Spinocerebellar Ataxia Type 3 in Peripheral Blood
Author(s) -
HübenerSchmid Jeannette,
Kuhlbrodt Kirsten,
Peladan Julien,
Faber Jennifer,
Santana Magda M.,
Hengel Holger,
Jacobi Heike,
Reetz Kathrin,
GarciaMoreno Hector,
Raposo Mafalda,
Gaalen Judith,
Infante Jon,
Steiner Katharina M.,
Vries Jeroen,
Verbeek Marcel M.,
Giunti Paola,
Pereira de Almeida Luis,
Lima Manuela,
Warrenburg Bart,
Schöls Ludger,
Klockgether Thomas,
Synofzik Matthis,
Riess Olaf
Publication year - 2021
Publication title -
movement disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.352
H-Index - 198
eISSN - 1531-8257
pISSN - 0885-3185
DOI - 10.1002/mds.28749
Subject(s) - spinocerebellar ataxia , ataxia , disease , trinucleotide repeat expansion , immunoassay , medicine , neurodegeneration , machado–joseph disease , neuroscience , biology , gene , immunology , genetics , allele , antibody
Background Spinocerebellar ataxia type 3 is a rare neurodegenerative disease caused by a CAG repeat expansion in the ataxin‐3 gene. Although no curative therapy is yet available, preclinical gene‐silencing approaches to reduce polyglutamine (polyQ) toxicity demonstrate promising results. In view of upcoming clinical trials, quantitative and easily accessible molecular markers are of critical importance as pharmacodynamic and particularly as target engagement markers. Objective We aimed at developing an ultrasensitive immunoassay to measure specifically polyQ‐expanded ataxin‐3 in plasma and cerebrospinal fluid (CSF). Methods Using the novel single molecule counting ataxin‐3 immunoassay, we analyzed cross‐sectional and longitudinal patient biomaterials. Results Statistical analyses revealed a correlation with clinical parameters and a stability of polyQ‐expanded ataxin‐3 during conversion from the pre‐ataxic to the ataxic phases. Conclusions The novel immunoassay is able to quantify polyQ‐expanded ataxin‐3 in plasma and CSF, whereas ataxin‐3 levels in plasma correlate with disease severity. Longitudinal analyses demonstrated a high stability of polyQ‐expanded ataxin‐3 over a short period. © 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society